Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
Status:
Recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
Triple-negative breast cancer (TNBC) is a special subtype of breast cancer that lacks the
expression of ER, PR, and Her-2 proteins, accounting for 15%-20% of all breast cancers.TNBC
patients do not benefit from endocrine therapy or HER-2-targeted therapy, but are sensitive
to cytotoxic drug therapy.Although the survival of TNBC patients has improved significantly
compared with the past, it is still the type with the worst prognosis among all subtypes of
breast cancer. Methods and drugs to further improve the therapeutic effect of TNBC patients
are still being explored.
Camrelizumab, a PD-1 inhibitor produced by Hengrui, has been approved for the treatment of
various malignant tumors including advanced lung cancer, advanced liver cancer and advanced
esophageal cancer. Shows good therapeutic effect and safety.
Therefore, this study intends to explore the superiority of camrelizumab on the basis of the
less toxic anthracycline-free TCb regimen.In order to provide more effective and safe
neoadjuvant therapy for lymph node-positive TNBC patients.